Das ist der Job
The Senior Director Commercial will further oversee the genera
Darum lohnt es sich
As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.
The incumbent needs to proactively recognize and address relevant systemic (e.g. health care structures, competitors, data gaps, diagnostic challenges, missing advocacy) and HCP related opportunities (e.g. therapeutic gaps, differentiation, economical attributes, clear messaging of patient‑ and physician‑relevant benefits).
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.
The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi‑selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C‑selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D‑selective inhibitor; and RMC-5127, a RAS(ON) G12V‑selective inhibitor, are currently in clinical development.
The Opportunity The Senior Director, Commercial Lead, UK is responsible for defining and executing the local commercial strategy for oncology products.
This role is accountable for building the commercial organization, driving launch and growth performance, and ensuring strong alignment across Medical Affairs, Market Access, and other key functions.
